ALLUVI: A DEEP DIVE INTO THE DRUG'S PROMISE

Alluvi, formerly LY3414901, represents a exciting advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable effectiveness in early trial data, with impressive reduction in weight ob